News and blogs
166 results found.
CAR-T therapies hold promise for cancers
Immunotherapy treatments called CAR-T therapies involve reprogramming a type of ‘supercharged’ immune cell could be mass-produced to help fight cancer.
Through the eye of a needle: Molecular immunology and anti-cancer drugs
Finding drugs that can target cancer cells but leave healthy cells unharmed is an ongoing problem in cancer research. At the University of Oxford, Professor Terry Rabbitts is exploring ways to create targeted drugs that work by blocking blood cancer proteins from interacting with healthy proteins – and the technique he’s developed for making these drugs could also have an impact on many other diseases. Read on to find out more…
CAR-T treatment turned down on NHS
The NHS medicines watchdog has recommended that a treatment called Kymriah should not be available to people with diffuse large B-cell lymphoma (DLBCL).
Blood cancer patients least likely to understand their diagnosis
How MPN disrupt work of blood stem cells
Blood Cancer UK researchers discover blood stem cells need to strike a delicate balance between making other types of blood cells and renewing themselves.
CLL - more people to benefit from ibrutinib in future
More people living with a type of leukaemia in England will soon have access to Ibrutinib, thanks to a successful campaign by Blood Cancer UK.
Blood cancers have longer diagnosis
A survey of patients treated for cancer on the NHS in England shows that blood cancers are still taking longer to be diagnosed than other types of cancer.
Blood cancer research breakthroughs
We look back on some of the biggest developments in blood cancer research that have led to improved NHScare for people with blood cancer.
Stem cell transplants without chemotherapy?
One option for treating or even curing blood cancers is a stem cell transplant. What if there was a less toxic way to get rid of these stem cells?
Leukaemia risk: babies with Down's syndrome
Professor Irene Roberts explains why new guidelines are needed to identify those children with Down's syndrome at risk of developing leukaemia.
New drug to improve leukaemia survival rates
A targeted cancer drug that reduces the chances of relapse for people with an aggressive type of leukaemia will be made available on the NHS in Scotland.
Genetic mutation 'likely cause' of childhood leukaemia
Blood Cancer UK-funded researchers say genetic mutation followed by infection is the most likely cause of the most common type of childhood leukaemia.
Three types of blood cancer treatment approved by NICE
NICE approves treatment for three types of blood cancer which will become routinely available on the NHS for people in England.
Chimeric antigen receptor T-cell therapy (CAR-T) could be made available on the NHS
Chimeric antigen receptor T-cell therapy (CAR-T) could be made available on the NHS this year.
British Society for Haematology Annual Meeting 2018 highlights
I spent 3 days at the British Society for Haematology Annual Meeting in Liverpool with Blood Cancer UK research team. Read about some exciting studies.
MP Jess Phillips meets top leukaemia scientists
The Birmingham Yardley MP met Professor Paul Moss and his team at the Institute of Immunology and Immunotherapy before World AML Awareness Day.
Scientists granted over £500,000 to tackle acute myeloid leukaemia AML
Two research projects are underway at the University of Cambridge that are seeking to find new ways to treat acute myeloid leukaemia (AML).
Childhood leukaemia - scientists map the genetic evolution
Key genetic events responsible for initiating the early stages of a type of childhood leukaemia have been identified by scientists in London.
Researchers work to treat chemotherapy-resistant leukaemia
Research shows treatment-resistance in aggressive blood cancer may be overcome by combining a new drug called venetoclax with chemotherapy.
NICE approves use of Gazyvaro for treatment of follicular lymphoma on NHS in England and Wales
NICE approves use of Gazyvaro for treatment of follicular lymphoma on NHS in England and Wales